UCB and Dermira Announce U.S. and EU Regulatory Submissions ...
(WorldNews Belgium)

The regulatory submissions for this new indication seek to expand the use of CIMZIA for the treatment of patients with moderate-to-severe chronic plaque psoriasis Data from three positive Phase 3 studies support the regulatory submissions Brussels, Belgium and Menlo Park, Calif., July 25, 2017 - UCB (Euronext: UCB) and Dermira, Inc. (NASDAQ: DERM) today announced the UCB submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for CIMZIA (certolizumab pegol). Separately, UCB also submitted a regulatory filing with the European Medicines Agency (EMA). Both regulatory filings seek to expand the approved indications for CIMZIA to include...